Abstract
The most common preclinical models of pancreatic cancer utilize immunodeficient hosts into which human xenografts are transplanted. The lack of an intact immune system alters the tumor microenvironment such that these models less accurately recapitulate human disease and therefore may not predict response to therapy in patients with pancreatic cancer. We sought to develop an immunocompetent mouse model of pancreatic cancer and to characterize its immunophenotype.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
